US6355681B2
(en)
*
|
1995-12-07 |
2002-03-12 |
Glytech, Inc. |
Glycine substitutes and precursors for treating a psychosis
|
US6512010B1
(en)
*
|
1996-07-15 |
2003-01-28 |
Alza Corporation |
Formulations for the administration of fluoxetine
|
US8022095B2
(en)
*
|
1996-08-16 |
2011-09-20 |
Pozen, Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
ATE369848T1
(de)
*
|
1998-04-14 |
2007-09-15 |
Gen Hospital Corp |
Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie
|
CA2345767A1
(en)
*
|
1998-10-16 |
2000-04-27 |
Paul Leonce Irma De Nijs |
Therapy for improving cognition
|
US6337328B1
(en)
*
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
DE19918105C1
(de)
*
|
1999-04-22 |
2000-09-21 |
Lohmann Therapie Syst Lts |
Transdermales therapeutisches System mit einem stark wirksamen Neuroleptikum
|
US7146209B2
(en)
*
|
2000-05-08 |
2006-12-05 |
Brainsgate, Ltd. |
Stimulation for treating eye pathologies
|
US6884910B2
(en)
*
|
2000-08-25 |
2005-04-26 |
Research Corporation Technologies, Inc. |
Uses for amino acid anticonvulsants
|
US6828351B2
(en)
*
|
2000-11-01 |
2004-12-07 |
Sention, Inc. |
Methods and compositions for regulating memory consolidation
|
US20030119884A1
(en)
*
|
2000-11-01 |
2003-06-26 |
Epstein Mel H. |
Methods and compositions for regulating memory consolidation
|
US20050059743A1
(en)
*
|
2000-11-01 |
2005-03-17 |
Sention, Inc. |
Methods for treating mild cognitive impairment and alzheimer's disease
|
US7619005B2
(en)
*
|
2000-11-01 |
2009-11-17 |
Cognition Pharmaceuticals Llc |
Methods for treating cognitive impairment in humans with Multiple Sclerosis
|
US20030232890A1
(en)
*
|
2000-11-01 |
2003-12-18 |
Sention, Inc. |
Methods for treating an impairment in memory consolidation
|
US20070117869A1
(en)
*
|
2000-11-01 |
2007-05-24 |
Cognition Pharmaceuticals Llc |
Methods for treating coginitive impairment and improving cognition
|
US20020155170A1
(en)
*
|
2000-11-30 |
2002-10-24 |
Walsh William John |
Nutrient supplements and methods for treating autism and for preventing the onset of autism
|
US20030185754A1
(en)
*
|
2001-01-16 |
2003-10-02 |
Genset, S.A. |
Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
|
US20030166554A1
(en)
*
|
2001-01-16 |
2003-09-04 |
Genset, S.A. |
Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
|
WO2005016319A2
(en)
*
|
2003-08-06 |
2005-02-24 |
Emory University |
Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
|
CA2442330A1
(en)
*
|
2001-03-29 |
2002-10-10 |
Emory University |
Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
|
WO2002087423A2
(en)
*
|
2001-05-02 |
2002-11-07 |
Blanchette Rockefeller Neurosciences Institute |
Carbonic anhydrase activators for enhancing learning and memory
|
EP1935414A3
(en)
*
|
2001-05-02 |
2010-08-18 |
Blanchette Rockefeller Neurosciences Institute |
Carbonic anhydrase activators for enhancig learning and memory
|
US7458374B2
(en)
|
2002-05-13 |
2008-12-02 |
Alexza Pharmaceuticals, Inc. |
Method and apparatus for vaporizing a compound
|
JP2005503425A
(ja)
*
|
2001-05-24 |
2005-02-03 |
アレックザ モレキュラー デリヴァリー コーポレイション |
所定の吸入ルートによる薬剤エステルの送出
|
US7645442B2
(en)
|
2001-05-24 |
2010-01-12 |
Alexza Pharmaceuticals, Inc. |
Rapid-heating drug delivery article and method of use
|
US20070122353A1
(en)
|
2001-05-24 |
2007-05-31 |
Hale Ron L |
Drug condensation aerosols and kits
|
US7766013B2
(en)
|
2001-06-05 |
2010-08-03 |
Alexza Pharmaceuticals, Inc. |
Aerosol generating method and device
|
US7498019B2
(en)
|
2001-05-24 |
2009-03-03 |
Alexza Pharmaceuticals, Inc. |
Delivery of compounds for the treatment of headache through an inhalation route
|
US7005138B2
(en)
*
|
2001-12-21 |
2006-02-28 |
Duramed Pharmaceuticals, Inc. |
Method of systematically delivering SSRIs
|
IL162666A0
(en)
|
2001-12-28 |
2005-11-20 |
Teva Pharma |
A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
|
BE1015608A6
(fr)
*
|
2003-07-15 |
2005-06-07 |
Messadek Jallal |
Traitement des arterites.
|
JPWO2003068215A1
(ja)
*
|
2002-02-14 |
2005-06-02 |
味の素株式会社 |
ミトコンドリア病用薬剤
|
EP1487542A1
(en)
*
|
2002-03-15 |
2004-12-22 |
H. Lundbeck A/S |
Use of asc-1 inhibitors to treat neurological and psychiatric disorders
|
US7684859B2
(en)
*
|
2002-04-25 |
2010-03-23 |
Brainsgate Ltd. |
Stimulation of the OTIC ganglion for treating medical conditions
|
AU2003240746A1
(en)
*
|
2002-06-10 |
2003-12-22 |
Evotec Neurosciences Gmbh |
Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases
|
KR100446503B1
(ko)
*
|
2002-06-19 |
2004-09-04 |
삼성전자주식회사 |
복합 억세스 포인트 장치 및 복합 억세스 포인트 장치를이용한 음성/데이터 패킷 처리 방법
|
US20050164400A1
(en)
*
|
2002-07-04 |
2005-07-28 |
Kenji Hashimoto |
Method of examining and diagnosing integration dysfunction syndrome
|
AU2003268026A1
(en)
|
2002-07-30 |
2004-02-16 |
Peter Migaly |
Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
|
FR2843590B1
(fr)
*
|
2002-08-14 |
2007-10-05 |
Prestwick Scient Capital Inc |
Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique
|
JP4745661B2
(ja)
|
2002-08-22 |
2011-08-10 |
大日本住友製薬株式会社 |
統合失調症治療剤
|
US7160913B2
(en)
|
2002-09-13 |
2007-01-09 |
Thomas Jefferson University |
Methods and kit for treating Parkinson's disease
|
US20040067986A1
(en)
*
|
2002-10-04 |
2004-04-08 |
Nathan Sassover |
Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
|
TWI319713B
(en)
|
2002-10-25 |
2010-01-21 |
|
Sustained-release tramadol formulations with 24-hour efficacy
|
JP2006514923A
(ja)
*
|
2002-10-25 |
2006-05-18 |
ファイザー・プロダクツ・インク |
注射可能な新規なデポ製剤
|
US8487002B2
(en)
*
|
2002-10-25 |
2013-07-16 |
Paladin Labs Inc. |
Controlled-release compositions
|
EP1585430B1
(en)
*
|
2002-11-14 |
2017-01-11 |
Brainsgate Ltd. |
Surgical tools and techniques for stimulation
|
US20040105818A1
(en)
|
2002-11-26 |
2004-06-03 |
Alexza Molecular Delivery Corporation |
Diuretic aerosols and methods of making and using them
|
US7913688B2
(en)
|
2002-11-27 |
2011-03-29 |
Alexza Pharmaceuticals, Inc. |
Inhalation device for producing a drug aerosol
|
EP1723957A3
(en)
|
2002-12-27 |
2013-01-23 |
Otsuka Pharmaceutical Co., Ltd. |
Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
|
AR042806A1
(es)
*
|
2002-12-27 |
2005-07-06 |
Otsuka Pharma Co Ltd |
Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
|
US20070249537A1
(en)
*
|
2003-01-23 |
2007-10-25 |
Supernus Pharmaceuticals, Inc. |
Absorption enhancing agents
|
IL154318A
(en)
*
|
2003-02-06 |
2010-05-31 |
Sarah Herzog Memorial Hospital |
Pharmaceutical compositions for the treatment of movement disorders
|
DK1615632T3
(da)
*
|
2003-04-17 |
2007-04-10 |
Jallal Messadek |
Flydende orale formularer for kontrolleret udskillelse af betain
|
JP2007502856A
(ja)
*
|
2003-05-16 |
2007-02-15 |
ファイザー・プロダクツ・インク |
精神病性障害および抑うつ性障害の治療
|
WO2004104490A1
(en)
|
2003-05-21 |
2004-12-02 |
Alexza Pharmaceuticals, Inc. |
Self-contained heating unit and drug-supply unit employing same
|
WO2004112700A2
(en)
*
|
2003-06-06 |
2004-12-29 |
The General Hospital Corporation |
Methods and compositions for modulating amyloid precursor protein translation
|
JP4624261B2
(ja)
|
2003-06-23 |
2011-02-02 |
大日本住友製薬株式会社 |
老人性痴呆症治療剤
|
NZ527142A
(en)
*
|
2003-07-23 |
2006-03-31 |
Douglas Pharmaceuticals Ltd |
A stable suspension formulation
|
US7838029B1
(en)
*
|
2003-07-31 |
2010-11-23 |
Watson Laboratories, Inc. |
Mirtazapine solid dosage forms
|
US20060128657A1
(en)
*
|
2003-08-04 |
2006-06-15 |
Jallal Messadek |
Selected betaines and their uses
|
US20060172006A1
(en)
*
|
2003-10-10 |
2006-08-03 |
Vincent Lenaerts |
Sustained-release tramadol formulations with 24-hour clinical efficacy
|
US20050096311A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
EP1713486A4
(en)
*
|
2003-12-02 |
2009-04-29 |
Sheldon Leslie James |
COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
|
WO2005062894A2
(en)
*
|
2003-12-23 |
2005-07-14 |
Darpharma, Inc. |
Co-administration of dopamine-receptor binding compounds
|
KR20070007276A
(ko)
|
2003-12-29 |
2007-01-15 |
제이슨 맥데빗 |
재발성 의학적 증상을 치료하기 위한 조성물 및 방법
|
US20120225916A1
(en)
*
|
2003-12-29 |
2012-09-06 |
Mcdevitt Jason P |
Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine
|
US20050171088A1
(en)
*
|
2004-01-30 |
2005-08-04 |
Astrazeneca Ab |
Treatment of psychoses with dibenzothiazepine antipsychotic
|
US8055347B2
(en)
|
2005-08-19 |
2011-11-08 |
Brainsgate Ltd. |
Stimulation for treating brain events and other conditions
|
US9233245B2
(en)
|
2004-02-20 |
2016-01-12 |
Brainsgate Ltd. |
SPG stimulation
|
US8010189B2
(en)
*
|
2004-02-20 |
2011-08-30 |
Brainsgate Ltd. |
SPG stimulation for treating complications of subarachnoid hemorrhage
|
WO2005080976A1
(ja)
|
2004-02-20 |
2005-09-01 |
Dainippon Sumitomo Pharma Co., Ltd. |
統合失調症の記憶・学習機能障害治療薬のin vivoスクリーニング方法
|
US7262318B2
(en)
*
|
2004-03-10 |
2007-08-28 |
Pfizer, Inc. |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
EP1735057B1
(en)
*
|
2004-03-22 |
2015-02-25 |
Apkarian Technologies LLC |
Method and compositions for treatment of chronic neuropathic pain
|
TW200538181A
(en)
|
2004-05-18 |
2005-12-01 |
Brni Neurosciences Inst |
Treatment of depressive disorders
|
US20050261278A1
(en)
*
|
2004-05-21 |
2005-11-24 |
Weiner David M |
Selective serotonin receptor inverse agonists as therapeutics for disease
|
US20050277626A1
(en)
*
|
2004-05-27 |
2005-12-15 |
Neurocure Ltd. |
Methods and compositions for treatment of nicotine dependence and dementias
|
US7540286B2
(en)
|
2004-06-03 |
2009-06-02 |
Alexza Pharmaceuticals, Inc. |
Multiple dose condensation aerosol devices and methods of forming condensation aerosols
|
EP1604656A1
(en)
|
2004-06-09 |
2005-12-14 |
Schwarz Pharma Ag |
Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
|
EP1768653A4
(en)
*
|
2004-06-25 |
2012-08-01 |
Univ Texas |
METHOD AND COMPOSITIONS FOR TREATING ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY AND HYPERPHENYL ALANINEMIA
|
US20050288340A1
(en)
*
|
2004-06-29 |
2005-12-29 |
Pfizer Inc |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
WO2006023702A2
(en)
*
|
2004-08-20 |
2006-03-02 |
Cypress Bioscience, Inc. |
Method for treating sleep related breathing disorders with setiptiline
|
US20090299418A1
(en)
*
|
2004-08-23 |
2009-12-03 |
Brainsgate Ltd. |
Concurrent bilateral spg modulation
|
WO2006034196A1
(en)
*
|
2004-09-17 |
2006-03-30 |
Lifelike Biomatic Inc. |
Compositions for enhancing memory and methods therefor
|
WO2006050581A2
(en)
*
|
2004-11-10 |
2006-05-18 |
Jallal Messadek |
Betaine as agent against arthropod - or mosquito -borne diseases
|
EP1827450A4
(en)
*
|
2004-11-17 |
2009-04-22 |
Cypress Bioscience Inc |
METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
|
WO2006060186A2
(en)
*
|
2004-11-30 |
2006-06-08 |
Bayer Pharmaceuticals Corporation |
Pyrazole derivatives for the treatment of dementia and related disorders
|
SI1830833T1
(sl)
*
|
2004-12-16 |
2010-05-31 |
Janssen Pharmaceutica Nv |
Kombinacija inhibitorja glicinskega transporterja GlyT in antipsihotika za zdravljenje simptomovshizofrenije in tudi njena priprava in njena uporaba
|
DE602005022764D1
(de)
|
2004-12-21 |
2010-09-16 |
Merck Sharp & Dohme |
Piperidin- und azetidinderivate als glyt1-inhibitoren
|
WO2006134341A1
(en)
*
|
2005-06-13 |
2006-12-21 |
Merck Sharp & Dohme Limited |
Therapeutic agents
|
US20100048653A1
(en)
*
|
2005-07-14 |
2010-02-25 |
The University Of British Columbia |
Neuroprotective modulation of nmda receptor subtype activities
|
US8795723B2
(en)
*
|
2005-09-09 |
2014-08-05 |
Angelini Pharma Inc. |
Sustained drug release compositions
|
ES2382818T3
(es)
|
2005-09-29 |
2012-06-13 |
Merck Sharp & Dohme Corp. |
Inhibidores de transportadores glicina radiomarcados
|
TW200806297A
(en)
*
|
2006-03-24 |
2008-02-01 |
Wyeth Corp |
Methods for treating cognitive and other disorders
|
US7884124B2
(en)
|
2006-06-30 |
2011-02-08 |
Sepracor Inc. |
Fluoro-substituted inhibitors of D-amino acid oxidase
|
WO2008013860A2
(en)
*
|
2006-07-28 |
2008-01-31 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use
|
US20090210026A1
(en)
*
|
2006-08-17 |
2009-08-20 |
Brainsgate Ltd. |
Spg stimulation for enhancing neurogenesis and brain metabolism
|
US20080081067A1
(en)
*
|
2006-10-03 |
2008-04-03 |
Gupta Manishkumar |
Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
|
US20100129805A1
(en)
*
|
2006-11-09 |
2010-05-27 |
Wai Lun Alan Fung |
Slc1a1 antipsychotic drug response markers
|
ES2594867T3
(es)
|
2007-03-09 |
2016-12-23 |
Alexza Pharmaceuticals, Inc. |
Unidad de calentamiento para usar en un dispositivo de administración de fármaco
|
WO2008118785A2
(en)
*
|
2007-03-23 |
2008-10-02 |
Tikvah Therapeutics |
Methods for treating depression using immediate-impact treatments and d-cycloserine
|
WO2008124814A2
(en)
*
|
2007-04-10 |
2008-10-16 |
Mcdevitt Jason P |
Sublingual formulations of d-cycloserine and methods of using same
|
US8198305B2
(en)
*
|
2007-04-13 |
2012-06-12 |
Concert Pharmaceuticals Inc. |
1,2-benzisoxazol-3-yl compounds
|
EP2167096A4
(en)
*
|
2007-06-13 |
2010-07-14 |
Cypress Bioscience Inc |
IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
|
US8580776B2
(en)
*
|
2007-07-10 |
2013-11-12 |
The Board Of Trustees Of The University Of Illinois |
Compositions and methods for treating neurodegenerating diseases
|
WO2009018368A1
(en)
*
|
2007-07-30 |
2009-02-05 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
|
US7860569B2
(en)
|
2007-10-18 |
2010-12-28 |
Brainsgate, Ltd. |
Long-term SPG stimulation therapy for prevention of vascular dementia
|
WO2009065193A1
(en)
*
|
2007-11-21 |
2009-05-28 |
Jallal Messadek |
Treatment of aspirin resistance with betaine and/or betaine enriched molasses
|
IL188681A0
(en)
*
|
2008-01-09 |
2008-12-29 |
Amino Acid Solutions Inc |
Pharmaceutical compositions and methods utilizing a d-amino acid
|
EP2111858A1
(en)
*
|
2008-04-25 |
2009-10-28 |
EPFL Ecole Polytechnique Fédérale de Lausanne |
Novel treatment for alzheimer's disease
|
GB0817379D0
(en)
*
|
2008-09-23 |
2008-10-29 |
Merck Sharp & Dohme |
New use
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
US20110237537A1
(en)
*
|
2009-05-29 |
2011-09-29 |
Lombard Jay L |
Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
|
US20120041066A1
(en)
*
|
2010-08-16 |
2012-02-16 |
Lombard Jay L |
Medical foods for the treatment of developmentally-based neuropsychiatric disorders via modulation of brain glycine and glutathione pathways
|
US8355927B2
(en)
|
2010-11-05 |
2013-01-15 |
Genomind, Llc |
Neuropsychiatric test reports
|
AU2010293364A1
(en)
*
|
2009-09-14 |
2012-03-08 |
Shiseido Company, Ltd. |
Composition for alleviating ultraviolet irradiation-induced damage
|
TWI544923B
(zh)
*
|
2009-12-29 |
2016-08-11 |
何應瑞 |
用於治療神經退化性疾病之醫藥組合物
|
WO2011104298A1
(en)
*
|
2010-02-24 |
2011-09-01 |
Universität Zürich |
Prevention and treatment of diseases caused by elevated levels of deoxy-sphingolipids
|
US8258139B2
(en)
|
2010-11-08 |
2012-09-04 |
Dainippon Sumitomo Pharma Co., Ltd. |
Method of treatment for mental disorders
|
WO2012065102A2
(en)
*
|
2010-11-12 |
2012-05-18 |
Promentis Pharmaceuticals, Inc. |
S-t-butyl protected cysteine di-peptide analogs and related compounds
|
US10583138B2
(en)
|
2012-07-12 |
2020-03-10 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
WO2012104852A1
(en)
*
|
2011-01-31 |
2012-08-09 |
Serotech, Llc |
Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
PT2782566T
(pt)
|
2011-11-21 |
2021-03-03 |
The Inst For Ethnomedicine |
L-serina para uso no tratamento de distúrbios neurodegenerativos
|
US20130296430A1
(en)
*
|
2012-05-03 |
2013-11-07 |
Antonio Hardan |
Compositions and methods for treating autism and autism spectrum disorder
|
KR101499299B1
(ko)
*
|
2012-08-03 |
2015-03-09 |
연세대학교 산학협력단 |
Shank2 유전자가 결실된 자폐증 모델 형질전환마우스 및 그 용도
|
AU2013299656C1
(en)
*
|
2012-08-07 |
2017-06-22 |
Buck Institute For Research On Aging |
Multi-component formulation for improving neurological function
|
US9265458B2
(en)
|
2012-12-04 |
2016-02-23 |
Sync-Think, Inc. |
Application of smooth pursuit cognitive testing paradigms to clinical drug development
|
US9380976B2
(en)
|
2013-03-11 |
2016-07-05 |
Sync-Think, Inc. |
Optical neuroinformatics
|
AT514349B1
(de)
*
|
2013-06-12 |
2018-05-15 |
Red Bull Gmbh |
Alpha-alkylierte Aminosäuren (AAAAs)
|
WO2015031493A1
(en)
*
|
2013-08-27 |
2015-03-05 |
The Johns Hopkins University |
Amino acid treatment of seizures
|
US9675796B2
(en)
|
2013-11-10 |
2017-06-13 |
Brainsgate Ltd. |
Implant and delivery system for neural stimulator
|
US9877951B2
(en)
|
2015-02-12 |
2018-01-30 |
College Of William And Mary |
Method for treating dementia
|
JP6822412B2
(ja)
|
2015-02-18 |
2021-01-27 |
アストン ユニヴァーシティー |
妊娠高血圧腎症のための診断アッセイ及び治療
|
AU2016258624B2
(en)
|
2015-05-04 |
2021-07-29 |
Confluence Pharmaceuticals, Llc |
Sprinkle formulations of acamprosate
|
US10271907B2
(en)
|
2015-05-13 |
2019-04-30 |
Brainsgate Ltd. |
Implant and delivery system for neural stimulator
|
SG10201914045QA
(en)
*
|
2015-08-04 |
2020-03-30 |
Confluence Pharmaceuticals Llc |
Combination therapy using acamprosate and d-cycloserine
|
US20170143681A1
(en)
|
2015-11-02 |
2017-05-25 |
Apkarian Technologies Llc |
Methods and compositions for treating pain
|
CN105476976B
(zh)
*
|
2015-12-22 |
2018-09-25 |
广州瑞尔医药科技有限公司 |
药物组合物及其制备方法和应用
|
IL263153B2
(en)
*
|
2016-05-25 |
2023-09-01 |
National Health Res Inst |
Method and composition to lower the psychotic and addictive disorder of ketamine
|
US9877942B1
(en)
*
|
2017-02-13 |
2018-01-30 |
Syneurx International (Taiwan) Corp. |
Co-crystals of substituted glycine and uses thereof
|
EP3624788A4
(en)
|
2017-05-17 |
2021-03-03 |
Confluence Pharmaceuticals, LLC |
FORMULATIONS OF HOMOTAURINS AND THEIR SALTS
|
KR102654569B1
(ko)
*
|
2017-05-25 |
2024-04-05 |
글리테크 엘엘씨. |
외상 후 스트레스 장애의 치료를 위한 제제
|
US10226442B2
(en)
*
|
2017-07-10 |
2019-03-12 |
Syneurx International (Taiwan) Corp. |
Lithium salts of N-substituted glycine compounds and uses thereof
|
CA3082834A1
(en)
*
|
2017-11-22 |
2019-05-31 |
Concert Pharmaceuticals, Inc. |
Deuterated analogs of d-serine and uses thereof
|
KR101952443B1
(ko)
*
|
2018-08-23 |
2019-02-26 |
주식회사 아스트로젠 |
신규한 마그네슘세리네이트 화합물 및 이의 용도
|
EP4241774A1
(en)
*
|
2020-11-04 |
2023-09-13 |
Gliacelltech Inc. |
Composition for preventing or treating neuroinflammatory diseases, comprising chlorpromazine
|
WO2023171106A1
(ja)
*
|
2022-03-08 |
2023-09-14 |
ソシウム株式会社 |
Tdp-43の凝集の抑制剤、tdp-43が過剰発現している細胞の細胞死の抑制剤、及びtdp-43の凝集を伴う疾患の治療又は予防剤
|